Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

946 - Phase 1 study of ipatasertib (AKT inhibitor) for investigating safety, tolerability, pharmacokinetics (PK), efficacy, and biomarkers in Japanese patients (pts) with solid tumors including castration-resistant prostate cancer (CRPC)

Date

11 Sep 2017

Session

Poster display session

Presenters

Shunji Takahashi

Citation

Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367

Authors

S. Takahashi1, Y. Fujiwara2, N. Matsubara3, J. Tomomatsu4, S. Iwasa2, A. Yamasaki5, C. Endo6, S. Yokoyama5, T. Doi7

Author affiliations

  • 1 Department Of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 - Tokyo/JP
  • 2 Department Of Experimental Therapeutics, National Cancer Center Hospital, Tokyo/JP
  • 3 Division Of Breast And Medical Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 4 Department Of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo/JP
  • 5 Clinical Development Div., Chugai pharmaceutical co., LTD., 103-8324 - Tokyo/JP
  • 6 Translational Clinical Research Div., Chugai pharmaceutical co., LTD., 103-8324 - Tokyo/JP
  • 7 Department Of Experimental Therapeutics, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
More

Resources

Abstract 946

Background

Ipatasertib is a highly selective small-molecule inhibitor of AKT showing antitumor activity. Clinical efficacy and safety in non-Japanese pts with metastatic CRPC has been reported (ASCO, ESMO 2016). We investigated safety, tolerability, PK, efficacy, and biomarkers in Japanese pts.

Methods

Phase 1, open label, dose-escalation study; 3 + 3 design. Primary endpoints were safety, tolerability, and PK. In Stage 1, pts with solid tumors were administered 200, 400, or 600 mg ipatasertib PO daily for 21 days of a 28-day cycle. In Stage 2, pts with CRPC were administered ipatasertib (200 or 400 mg PO daily) in combination with abiraterone acetate (AA) (1000 mg PO daily) plus prednisolone (5 mg PO twice a day) for the whole 28-day cycle. In an exploratory analysis of biomarkers, we investigated the relationship between PI3K pathway alterations (PIK3CA mutation or amplification and PTEN loss) and clinical efficacy of ipatasertib.

Results

A total of 21 pts were enrolled. Stage 1: 3, 4, and 8 pts were enrolled in the 200, 400, and 600 mg cohorts. One pt in the 600 mg cohort experienced DLT [Gr3 nausea]. The most common AEs of any grade (≥30% of pts) were nausea, diarrhea, decreased appetite, vomiting, and fatigue. Cmax and AUC of ipatasertib were dose-proportional from 200 to 600 mg. Eight pts had stable disease (SD); 2 of those 8 pts continued study treatment beyond 4 months. Stage 2: 3 pts each were enrolled in the 200 and 400 mg cohorts. No DLTs were observed. The most common AEs of any grade were nausea, diarrhea, vomiting, diabetes mellitus, dysgeusia, and dizziness. Ipatasertib Cmax and AUC were similar to those in monotherapy. Of the 6 pts, complete response was observed in 1 pt and SD was observed in 1 pt. Three pts continued study treatment beyond 4 months; 2 of those 3 pts had previously received AA and enzalutamide. Biomarker results will be presented.

Conclusions

Ipatasertib was well tolerable for Japanese pts. Based on our results, the recommended doses of ipatasertib for further development are 600 mg for monotherapy and 400 mg for in combination with AA plus prednisolone.

Clinical trial identification

JapicCTI-152910, 22-May-2015

Legal entity responsible for the study

Chugai Pharmaceutical co., LTD.

Funding

Chugai Pharmaceutical co., LTD.

Disclosure

S. Takahashi: Corporate-sponsored Research: AstraZeneca, MSD, Taiho, Chugai, Novartis, Daiichi-Sankyo, Bayer, Parexel, Ono. Y. Fujiwara: Advisory Board: Bristol-Myers Squibb, Ono. Corporate-sponsored Research: AstraZeneca, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GlaxoSmithKline (GSK), MerckSerono, MSD. N. Matsubara: Advisory Board: Janssen Pharma, Sanofi. Corporate-sponsored Research: Janssen Pharma, Bayer, MSD, Chugai, Taiho, Sanofi. J. Tomomatsu: Industrial Physician: Eisai. S. Iwasa: Corporate-sponsored Research: Eli Lilly, Daiichi-Sankyo, Novartis, Bristol-Myers Squibb, Chugai, Eisai. A. Yamasaki: Employee of Chugai. C. Endo, S. Yokoyama: Employee and Stock ownership: Chugai. T. Doi: Advisory Board: Eli Lilly, MSD, Amgen, Daiichi-Sankyo. Corporate-sponsored Research: Eli Lilly, Taiho, Novartis, Merck Serono, MSD, Boehringer Ingelheim, Pfizer, Sumitomo Dainippon, Chugai, Kyowa Hakko Kirin, Daiichi-Sankyo, Celgene, Quintiles, Janssen, Astellas.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.